Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes

Abstract Bufalin was reported to show strong pharmacological effects including cardiotonic, antiviral, immune-regulation, and especially antitumor effects. The objective of this study was to determine the characterization, antitumor efficacy, and pharmacokinetics of bufalin-loaded PEGylated liposome...

Full description

Bibliographic Details
Published in:	Nanoscale Research Letters
Main Authors:	Jiani Yuan, Xuanxuan Zhou, Wei Cao, Linlin Bi, Yifang Zhang, Qian Yang, Siwang Wang
Format:	Article
Language:	English
Published:	SpringerOpen 2017-11-01
Subjects:	Bufalin PEGylated liposome High-pressure homogenization Pharmacokinetics
Online Access:	http://link.springer.com/article/10.1186/s11671-017-2346-8

Similar Items

Bufalin-Loaded PEGylated Liposomes: Antitumor Efficacy, Acute Toxicity, and Tissue Distribution
by: Jiani Yuan, et al.
Published: (2019-07-01)

Towards the Development of Long Circulating Phosphatidylserine (PS)- and Phosphatidylglycerol (PG)-Enriched Anti-Inflammatory Liposomes: Is PEGylation Effective?
by: Miriam E. Klein, et al.
Published: (2021-02-01)

Effect of PEGylation on the physicochemical and pharmacokinetic characteristics of bovine serum albumin-encapsulated liposome
by: Yuko Okamoto, et al.
Published: (2016-02-01)

PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study
by: Shirleide Santos Nunes, et al.
Published: (2022-01-01)

In Vitro Study of Antitumor and Antimicrobial Activity of a Preparation of Pegylated Liposomes with Sanguinarine
by: S. V. Lutsenko, et al.
Published: (2020-05-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01)

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis
by: Donghao Tang, et al.
Published: (2024-01-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004-09-01)

Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone
by: Karen Ocaña-Arakachi, et al.
Published: (2023-09-01)

The pH-Responsive Liposomes—The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells
by: Eirik A. L. Rustad, et al.
Published: (2022-05-01)

Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer
by: Die Zhang, et al.
Published: (2023-03-01)

Diffuse Erythematous Follicular Eruption Induced by Pegylated Liposomal Doxorubicin
by: Zhong L, et al.
Published: (2025-04-01)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
by: Yuanyuan Shen, et al.
Published: (2024-12-01)

Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications
by: Hwankyu Lee
Published: (2020-06-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
by: Xia LIU, et al.
Published: (2009-12-01)

PEGylated Liposomes of Disulfiram and Paclitaxel: A Promising Chemotherapeutic Combination Against Chemoresistant Breast Cancer
by: Ammar Said Suliman, et al.
Published: (2025-03-01)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
by: Guilherme S. Ramos, et al.
Published: (2022-05-01)

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
by: Qingmei Ye, et al.
Published: (2023-10-01)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
by: Hiroyuki Yoshida, et al.
Published: (2023-07-01)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01)

Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy
by: Yibao Fan, et al.
Published: (2024-09-01)

Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug
by: Lim C, et al.
Published: (2023-03-01)

Phase I Trial of Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Advanced Soft Tissue Sarcoma
by: Ye T, et al.
Published: (2025-08-01)

Hydrophobic Drug-Loaded PEGylated Magnetic Liposomes for Drug-Controlled Release
by: Andri Hardiansyah, et al.
Published: (2017-05-01)

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro
by: Huan Tang, et al.
Published: (2023-03-01)

Bufalin-Mediated Regulation of Cell Signaling Pathways in Different Cancers: Spotlight on JAK/STAT, Wnt/β-Catenin, mTOR, TRAIL/TRAIL-R, and Non-Coding RNAs
by: Ammad Ahmad Farooqi, et al.
Published: (2023-02-01)

Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies
by: Khrystyna Levytska, et al.
Published: (2025-04-01)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
by: Mohamed F. Zaky, et al.
Published: (2023-06-01)

Effect of Bufalin on Proliferation and Apoptosis of Human Non-small Cell Lung Cancer A549 Cell
by: Zhitu ZHU, et al.
Published: (2010-09-01)

Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis
by: Christopher W. Hoeger, et al.
Published: (2025-07-01)

Enhancing targeted delivery and efficacy of PEGylated liposomal doxorubicin with liposomal minoxidil: comprehensive in silico, in vitro, and in vivo tumor model studies
by: Vahideh Mohammadzadeh, et al.
Published: (2025-12-01)

Comparative Pharmacokinetics of Cinobufacini Capsule and Injection by UPLC-MS/MS
by: Ming Li, et al.
Published: (2022-07-01)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
by: Han Yao, et al.
Published: (2023-06-01)

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
by: Zhen-zhou SHEN, et al.
Published: (2010-02-01)

Adhesion and Structural Changes of PEGylated Lipid Nanocarriers on Silica Surfaces
by: Philipp Grad, et al.
Published: (2021-07-01)

Bufalin Inhibits Cellular Proliferation and Cancer Stem Cell-Like Phenotypes via Upregulation of MiR-203 in Glioma
by: Tao Liu, et al.
Published: (2017-11-01)

Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer
by: Jinbao Chen, et al.
Published: (2025-02-01)